drugset

drugset / Trial / NCT00298883

Desensitization of Renal Transplant Candidates

NCT00298883 ↗

Phase 1 Completed 9 enrolled University of Florida Novartis · collab

NaSingle-groupOpen-labelTreatment

Summary

Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation.

Timeline

Start: 2006-02
Primary completion: 2008-08
Completion: 2008-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mycophenolic acid	Small molecule	360 mg	Oral

Indications